STOCK TITAN

Arcellx, Inc. - ACLX STOCK NEWS

Welcome to our dedicated page for Arcellx news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on Arcellx stock.

Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biotechnology company dedicated to transforming cell therapy by developing innovative immunotherapies for patients with cancer and other incurable diseases. By harnessing advanced scientific techniques, Arcellx is reimagining cell therapy to be safer, more effective, and widely accessible.

Arcellx's flagship product candidate, CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel), is a BCMA-specific CAR-modified T-cell therapy aimed at treating relapsed or refractory multiple myeloma (rrMM). The innovative D-Domain binding technology used in anito-cel is designed to enhance target specificity and binding affinity, potentially improving therapeutic outcomes. In ongoing clinical studies, anito-cel has demonstrated remarkable efficacy, achieving a 100% overall response rate and a 76% complete response rate in patients with poor prognostic factors.

Arcellx is also making strides with its ARC-SparX platform, which includes two clinical-stage programs: ACLX-001 for rrMM and ACLX-002 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. These programs highlight Arcellx's commitment to developing dosable and controllable CAR-T therapies that address unmet medical needs.

In collaboration with Kite, a Gilead Company, Arcellx is co-developing and co-commercializing anito-cel for the treatment of multiple myeloma. This partnership not only strengthens their financial footing but also accelerates the clinical development and potential commercial launch of anito-cel. Kite's extensive experience in CAR T-cell therapy manufacturing and commercialization complements Arcellx's cutting-edge research, creating a synergistic force in the cell therapy landscape.

Arcellx has a robust pipeline and a solid financial position, with cash, equivalents, and marketable securities expected to fund operations into 2027. The company is on track to initiate the global Phase 3 trial iMMagine-3 in the second half of 2024, aimed at further validating anito-cel's efficacy and safety compared to standard of care treatments in a diverse patient population.

For more detailed information, visit www.arcellx.com and follow Arcellx on X (formerly Twitter, @arcellx) and LinkedIn.

Rhea-AI Summary

Arcellx (NASDAQ: ACLX) announced clinical data from its Phase 1 and iMMagine-1 studies for anitocabtagene autoleucel (anito-cel) in relapsed/refractory multiple myeloma patients. The Phase 1 study showed a 30.2-month median progression-free survival with 38.1 months median follow-up. The Phase 2 iMMagine-1 study demonstrated 95% overall response rate and 62% complete response rate in 58 patients at 10.3 months median follow-up. No delayed neurotoxicities were observed in over 140 patients across both studies. The company also reported the first patient dosing in the iMMagine-3 study, manufactured by Kite.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences clinical trial
-
Rhea-AI Summary

Arcellx (NASDAQ: ACLX) reported its Q2 2024 financial results and business updates. Key highlights include:

- Earned a $68M milestone payment from Kite for iMMagine-1 enrollment
- Submitted an abstract for iMMagine-1 study at the 66th ASH Annual Meeting
- Kite initiated the global Phase 3 trial, iMMagine-3
- FDA cleared anito-cel IND application for myasthenia gravis

Financial highlights:
- Cash position: $646.8M, funding operations into 2027
- Collaboration revenue: $27.4M, up from $14.3M in Q2 2023
- R&D expenses: $41.0M, up from $28.3M in Q2 2023
- G&A expenses: $21.4M, up from $15.5M in Q2 2023
- Net loss: $27.2M, compared to $23.9M in Q2 2023

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.31%
Tags
-
Rhea-AI Summary

Arcellx and Kite, in partnership with Gilead Company, announced updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program. The global Phase 3 trial, iMMagine-3, will evaluate anito-cel in patients with relapsed and/or refractory multiple myeloma exposed to specific previous treatments. The technical transfer for manufacturing anito-cel is complete, and preliminary data from the iMMagine-1 trial is expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
Rhea-AI Summary

Kite, a Gilead Company, and Arcellx, Inc. announced operational updates on their anito-cel multiple myeloma program. They shared the iMMagine-3 trial design, manufacturing details, and plans to present data from the iMMagine-1 trial. Anito-cel is a BCMA CAR T cell therapy for relapsed/refractory multiple myeloma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Summary

Arcellx, Inc. (NASDAQ: ACLX) reported financial highlights for Q1 2024, with $691.0 million in cash, collaboration revenue of $39.3 million, R&D expenses down by $0.6 million, G&A expenses up by $7.3 million, and a net loss of $7.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
-
Rhea-AI Summary

Arcellx, a biotechnology company focused on innovative immunotherapies for cancer, will participate in two upcoming investor conferences: BofA Securities Health Care Conference 2024 and TD Cowen 5th Annual Oncology Innovation Summit. The company aims to enhance its investor relations through these engagements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
conferences
Rhea-AI Summary
Arcellx, Inc. (ACLX) will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on developing innovative immunotherapies for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
-
Rhea-AI Summary
Arcellx, Inc. (ACLX) to participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. The company focuses on developing innovative immunotherapies for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
-
Rhea-AI Summary
Arcellx, Inc. (ACLX) will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference. The discussion will focus on the development of innovative immunotherapies for cancer and other diseases. A live webcast will be available on Arcellx's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
Rhea-AI Summary
Arcellx, Inc. reported significant business and financial achievements for Q4 and full year 2023, including an expanded partnership with Kite Pharma, robust long-term responses from anito-cel Phase 1 trial, and ending the quarter with $729.2M cash. The company's continued progress in cell therapy development and strategic collaborations position it for future growth and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags

FAQ

What is the current stock price of Arcellx (ACLX)?

The current stock price of Arcellx (ACLX) is $92.98 as of November 6, 2024.

What is the market cap of Arcellx (ACLX)?

The market cap of Arcellx (ACLX) is approximately 4.9B.

What is Arcellx, Inc.?

Arcellx, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for patients with cancer and other incurable diseases.

What is the lead product candidate of Arcellx?

Arcellx's lead product candidate is anitocabtagene autoleucel (anito-cel), a BCMA-specific CAR-modified T-cell therapy for relapsed or refractory multiple myeloma.

What are the latest clinical trial updates for anito-cel?

Anito-cel has shown a 100% overall response rate and 76% complete response rate in patients with relapsed or refractory multiple myeloma. The Phase 3 iMMagine-3 trial is set to begin in the second half of 2024.

Who are Arcellx's key partners?

Arcellx has a strategic partnership with Kite, a Gilead Company, to co-develop and co-commercialize anito-cel for multiple myeloma.

What is ARC-SparX?

ARC-SparX is Arcellx's platform for dosable and controllable CAR-T therapies, currently in Phase 1 trials for multiple myeloma and acute myeloid leukemia.

What is the financial outlook for Arcellx?

Arcellx has a solid financial position, with cash, cash equivalents, and marketable securities expected to fund operations into 2027.

What designations has anito-cel received?

Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

What is the iMMagine-3 trial?

iMMagine-3 is a global Phase 3 randomized controlled trial designed to compare the efficacy and safety of anito-cel with standard of care in patients with relapsed or refractory multiple myeloma.

How can I get more information about Arcellx?

For more information, visit Arcellx's website at www.arcellx.com and follow them on X (formerly Twitter, @arcellx) and LinkedIn.

What recent collaborations has Arcellx announced?

Arcellx recently expanded its collaboration with Kite to include the development of anito-cel for lymphomas and received a $200 million equity investment.

Arcellx, Inc.

Nasdaq:ACLX

ACLX Rankings

ACLX Stock Data

4.93B
53.76M
12.75%
95.55%
7.75%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
REDWOOD CITY